GFAP and Alzheimer disease: Furthermore, in participants with neuropathologically confirmed AD at autopsy, we observed that plasma GFAP levels are elevated relative to cognitively normal (CN) individuals and intermediate in those who remain cognitively unimpaired despite significant levels of AD pathology (ASYMAD).